{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T17:22:20Z","timestamp":1768324940260,"version":"3.49.0"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>The effectiveness of a vaccination program is influenced by its design and implementation details and by the target population characteristics. Using routinely collected population\u2010based individual\u2010level data, we assessed the effectiveness (against cervical dysplasia) of Manitoba's quadrivalent human papillomavirus (qHPV) routine school\u2010based vaccination program and a short\u2010lived campaign that targeted women at high\u2010risk of developing cervical cancer. Females \u22659 years old who received the qHPV vaccine in Manitoba (Canada) between September 1, 2006, and March 31, 2013 (N\u2009=\u200931,442) were matched on age and area of residence to up to three unvaccinated females. Cox proportional hazards models were used to estimate qHPV VE against high\u2010grade (HSILs) and low\u2010grade squamous intraepithelial lesions (LSILs) and atypical squamous cells of undetermined significance (ASCUS). Among 14\u201317\u2010year\u2010old participants who had Pap cytology after enrollment, the adjusted qHPV VE estimates were 30% (17\u201358%) and 36% (21\u201348%) against the detection of HSILs and LSILs, respectively. There was, however, no evidence of program effectiveness among females vaccinated at \u226518\u2009years of age and among those with a history of abnormal cytology, who were mostly vaccinated as part of the high\u2010risk program. Estimates of VE for females vaccinated in the school\u2010based program are consistent with the expected benefits from qHPV vaccination. No similar benefits were detected among women vaccinated at an older age, and those with abnormal cytology, who were targeted by the high\u2010risk program. Further efforts should be targeted at achieving higher vaccine coverage among preadolescents, prior to the initiation of sexual activity.<\/jats:p>","DOI":"10.1002\/ijc.32135","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T16:50:52Z","timestamp":1547743852000},"page":"671-677","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness of school\u2010based and high\u2010risk human papillomavirus vaccination programs against cervical dysplasia in Manitoba, Canada"],"prefix":"10.1002","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8472-932X","authenticated-orcid":false,"given":"Christiaan H.","family":"Righolt","sequence":"first","affiliation":[{"name":"Vaccine and Drug Evaluation Centre, Department of Community Health Sciences University of Manitoba  Winnipeg MB Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songul","family":"Bozat\u2010Emre","sequence":"additional","affiliation":[{"name":"Vaccine and Drug Evaluation Centre, Department of Community Health Sciences University of Manitoba  Winnipeg MB Canada"},{"name":"Epidemiology and Surveillance Manitoba Health, Seniors and Active Living, Government of Manitoba  Winnipeg MB Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6574-0574","authenticated-orcid":false,"given":"Salaheddin M.","family":"Mahmud","sequence":"additional","affiliation":[{"name":"Vaccine and Drug Evaluation Centre, Department of Community Health Sciences University of Manitoba  Winnipeg MB Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1363\/3600604"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.05.039"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20244"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/597071"},{"key":"e_1_2_9_7_1","unstructured":"Public Health Branch Manitoba Health Healthy Living and Seniors Human Papillomavirus (HPV) Information for Health Professionals 2013."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1625"},{"key":"e_1_2_9_9_1","unstructured":"National Advisory Committee on Immunization (NACI) Update on the recommended Human Papillomavirus (HPV) vaccine immunization schedule. An Advisory Committee Statement (ACS) 2014."},{"key":"e_1_2_9_10_1","unstructured":"Public Health Agency of Canada Vaccine coverage in Canadian children: Results from the 2013 childhood National Immunization Coverage Survey (cNICS) 2017."},{"key":"e_1_2_9_11_1","unstructured":"Manitoba Health Public Health and Primary Health Care Division Communicable Disease Control.2012."},{"key":"e_1_2_9_12_1","first-page":"341","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"3493","author":"Group FIIS","year":"2010","journal-title":"BMJ"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061741"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-13"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw354"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1458"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt460"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30035"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-2961"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jog.13419"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-227"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.4645"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199303000-00002"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.84.10.1666"},{"key":"e_1_2_9_25_1","unstructured":"Fransoo R MP The Need To Know TEam PriorH CurchillC KosevaI BaillyA AllegroE The 2013 RHA Indicators Atlas. Manitoba Centre for Health Policy 2013."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000742"},{"key":"e_1_2_9_27_1","volume-title":"Defining and validating chronic diseases: an administrative data approach","author":"Lix L","year":"2006"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22527"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.026"},{"key":"e_1_2_9_30_1","unstructured":"Partners in Planning for Healthy Living 2012\u20132013 Manitoba Youth Health Survey Report2014."},{"key":"e_1_2_9_31_1","unstructured":"Manitoba Health Public Health and Primary Health Care Division Communicable Disease Control 2014."},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1609-1"},{"key":"e_1_2_9_33_1","unstructured":"CancerCare Manitoba. Guidelines for Breast Cervical and Colorectal Cancer Screening ed. 2013."},{"key":"e_1_2_9_34_1","unstructured":"Canadian Partnership Against Cancer. Cancer system performance 2017 Report.2017."}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.32135","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.32135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T15:00:24Z","timestamp":1694358024000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.32135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1002\/ijc.32135"],"URL":"https:\/\/doi.org\/10.1002\/ijc.32135","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,7]]},"assertion":[{"value":"2018-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}